Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT05234723
Recruiting Observational

Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients

NCT05234723 · tracked via the Priya Life Science Spain tracker
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase
Observational
Started
2023-06-19
Last updated
2026-06-15

Condition(s) studied

Cytomegalovirus Infections

Study summary

The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). Aims of the study are to investigate the incidence of and risk factors for GCV-RR CMV infection in SOT recipients and HSCT patients in order to design further studies aimed at preventing and improving the patient management of GCV-RR CMV infections.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * All adult (≥ 18 years) patients who underwent SOT or HSCT developing CMV-infection treated with GC/VGC * Ability to understand the purpose of the study and provide signed and dated informed consent Exclusion Criteria: * Lack of clinical and/or laboratory data regarding the type of CMV event * Lack of the serological mismatch at transplantation * Lack of the type of SOT or HSCT * Lack of the patient and graft outcome at 30, 60 or 90 days after CMV event diagnosis

Primary outcome measure(s)

Trial sites (23)

FacilityCityRegionStatus
MD Anderson Cancer Center Houston Texas Not Yet Recruiting
Institut Jules Bordet Brussels Belgium Not Yet Recruiting
University Hospitals Leuven Leuven Belgium Not Yet Recruiting
Helsinki University Central Hospital Helsinki Helsinki Not Yet Recruiting
Centre Hospitalier Universitaire de Limoges Limoges Limoges Not Yet Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna Bologna Recruiting
Humanitas Research Hospital Rozzano Milano Not Yet Recruiting
Istituto mediterraneo per i trapianti e terapie ad alta specializzazione (ISMETT) Palermo Palermo Recruiting
Ospedale San Martino Genova Italy Not Yet Recruiting
Policlinico di Milano Milan Italy Recruiting
Azienda Ospedaliero-Universitaria di Modena Modena Italy Recruiting
Azienda Ospedaliera dei Colli Naples Italy Not Yet Recruiting
Azienda Ospedale-Università Padova Padova Italy Not Yet Recruiting
AOU Città della salute e della scienza Torino Italy Recruiting
ASST dei Sette Laghi Varese Italy Not Yet Recruiting
São João University Hospital Porto Portugal Not Yet Recruiting
Hospital Clinic Barcelona Spain Recruiting
Instituto Maimónides de Investigación Biomédica de Córdoba Córdoba Spain Recruiting
Gregorio Marañón General University Hospital Madrid Spain Not Yet Recruiting
University Hospital 12 de Octubre Madrid Spain Not Yet Recruiting
Centre hospitalier universitaire vaudois (CHUV) Lausanne Lausanne Not Yet Recruiting
University Hospital Zurich Zurich Switzerland Not Yet Recruiting
Manchester University NHS Foundation Trust Manchester United Kingdom Not Yet Recruiting

More IRCCS Azienda Ospedaliero-Universitaria di Bologna trials in Spain

PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE Recruiting
Study on Post-acute Myocardial Infarction Ventricular Defect: Outcome Evalutation in Relation to Surgical Timing Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05234723 on ClinicalTrials.gov ↗ ← All trials in Spain